ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (AMEX:RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, today announced that the U.S. Patent & Trademark Office has issued to the Company U.S. Patent 7,388,014, entitled "Quinazoline Derivatives and Therapeutic Use Thereof."
